# Tackling Undruggable Cancer Targets using Chemoproteomic Platforms

> **NIH NIH R35** · UNIVERSITY OF CALIFORNIA BERKELEY · 2022 · $928,230

## Abstract

One of the biggest challenges facing cancer drug discovery is that >90 % of the proteome is
currently considered “undruggable” because most proteins do not possess known binding
pockets or “ligandable hotspots” that can be pharmacologically and functionally targeted for
therapeutic benefit 1. Tackling the undruggable proteome requires the development of
innovative technologies for ligand discovery AND the discovery of novel therapeutic modalities
to functionally manipulate the undruggable proteome for therapeutic benefit. The Nomura
Research Group is focused on reimagining druggability by advancing and applying
chemoproteomic platforms to tackle the undruggable proteome, towards developing
next-generation therapies and therapeutic modalities for cancer.

## Key facts

- **NIH application ID:** 10518755
- **Project number:** 1R35CA263814-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA BERKELEY
- **Principal Investigator:** Daniel Nomura
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $928,230
- **Award type:** 1
- **Project period:** 2022-08-01 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10518755

## Citation

> US National Institutes of Health, RePORTER application 10518755, Tackling Undruggable Cancer Targets using Chemoproteomic Platforms (1R35CA263814-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10518755. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*